v3.26.1
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2025
Dec. 31, 2024
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Proceeds from Sale of Equity Securities, FV-NI   $ 0 $ 74,047
Realized gain on sale of equity securities   $ 0 $ 32,139
Vaxcyte, Inc. | Vaxcyte Common Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Number of shares held   0 0
Investment, Type [Extensible Enumeration]     Equity Securities [Member]
Proceeds from Sale of Equity Securities, FV-NI     $ 74,000
Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement, Shares     667,780
Realized gain on sale of equity securities     $ 32,100
Blackstone Life Sciences | Royalty | 2015 License Agreement      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Revenue interest percentage 4.00% 4.00%